Corvus Pharmaceuticals
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
863 Mitten Rd Ste 102, Burlingame, Calif...Phone Number
(650) 900-4520Website
www.corvuspharma.comRevenue
-Stock Symbol
CRVSIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus focuses on bringing medicines to patients with the most difficult-to-treat cancers. Corvus is headquartered in Burlingame, California.Explore more
Corvus Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Corvus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Corvus Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Check if Corvus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Corvus Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Corvus Pharmaceuticals
Earning: See what the market has to say on Corvus Pharmaceuticals recently announced quarterly report
Corvus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Corvus Pharmaceuticals had a recent Job posting/layoffs
Check out if Corvus Pharmaceuticals is spiking on competitors!
Recommended Actions
Find VP level buyers at Corvus Pharmaceuticals
Find 3 more new buyers
Compare Similar Companies to Corvus Pharmaceuticals
Compare insights from companies similar to Corvus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Corvus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Corvus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Corvus Pharmaceuticals.
Corvus Pharmaceuticals financials insights
Gather financial insights about Corvus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$33.5M
2015
Series B
$75M
2016
Stock Offering
$71M
2018
Stock Offering
$64.8M
Corvus Pharmaceuticals Tech Stack
A closer look at the technologies used by Corvus Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Partnership
Corvus Pharmaceuticals has partnered with Angel to cover ex-US rights for Socalinib, primarily in China, with Corvus holding a 46% ownership stake in Angel. Angel is running a Phase 1b/2b program in atopic dermatitis evaluating low and high doses at QD versus BID, with Cohort 1 data expected by end of year.
Partnership
Project
Corvus Pharmaceuticals is conducting the CR1 Phase 2 trial, a global 200-patient study of Socalinib for atopic dermatitis across more than 70 sites in North America and Europe, with a data readout expected in Q3 2027.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Spending/Investment
Hiring Plans
Hiring Plans
Corvus Pharmaceuticals News & Media
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTCorvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Immuno-oncology specialist Corvus Pharmaceuticals reported a recent insider buy amid a year of sharp share price gains.Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States $13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United StatesCorvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 11:20 AM EDTCompany ParticipantsJeffrey Arcara...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Corvus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus focuses on bringing medicines to patients with the most difficult-to-treat cancers. Corvus is headquartered in Burlingame, California.... Read More
